Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TScan Therapeutics ( (TCRX) ) has shared an announcement.
On November 3, 2025, TScan Therapeutics announced a strategic shift to prioritize its hematologic malignancies program, pausing enrollment in its solid tumor trial and focusing on preclinical efforts for solid tumors and autoimmunity target discovery. This decision, following a positive meeting with the FDA regarding the pivotal trial design for TSC-101, includes a 30% workforce reduction, aiming to save $45 million annually in 2026 and 2027, and extends the company’s cash runway into the second half of 2027.
The most recent analyst rating on (TCRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.
Spark’s Take on TCRX Stock
According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.
The overall stock score for TScan Therapeutics is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis provides a mixed outlook with some positive momentum indicators, while valuation remains a concern due to the negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not impact the score.
To see Spark’s full report on TCRX stock, click here.
More about TScan Therapeutics
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment.
Average Trading Volume: 424,129
Technical Sentiment Signal: Hold
Current Market Cap: $110.1M
For a thorough assessment of TCRX stock, go to TipRanks’ Stock Analysis page.